article

Issue #2 2014 – Digital edition

Posted: 15 April 2014 |

In Issue #2 2014: Mass Spectrometry and Stem Cells in-depth focuses, Hot Melt Extrusion, PAT, Excipients, Microbiology plus much more…

European Pharmaceutical Review - Issue 2 2014
  • Foreword: Is risk in the eye of the beholder?
    David Elder, GlaxoSmithKline & JPAG
  • Microbiology: Antimicrobial delivery
    Joshua Boateng and Harshavardhan Pawar, Department of Pharmaceutical Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich
  • Hot Melt Extrusion: Hot melt extrusion processing for the development of sustained release products
    Dennis Douroumis, Reader in Pharmaceutical Sciences at the University of Greenwich and the Director of Centre for Innovation in Process Engineering and Research
  • Mass Spectrometry in-depth focus: Featuring articles from Paul Gates, University of Bristol who looks at electrospray mass spectrometry and its use in characterising natural products and Ioannis Papayannopoulos from Targanox who discusses mass spectrometry in the biopharmaceutical industry. We also preview the 62nd ASMS Conference on Mass Spectrometry and Allied Topics.
  • Process Analytical Technology: PAT for packaging: review of applications for expeditious, non-destructive quality testing
    Jose Montenegro-Alvarado, Bradley Diehl, Jean-Maxime Guay, Steve Hammond, Hiwot Isaac, Ben Lyons, Conor McSweeney, Seamus O’Neill, Jean-Sebastien Simard and Joep Timmermans, Pfizer Inc.
  • Stem Cells In-depth focus: Sarah Baird from the University of Otago reviews mesenchymal stem cells in cancer therapy while Graham Kelly, CEO of Novogen and Gil Mor, Yale University School of Medicine look at ovarian cancer stem cells. We also preview ISSCR’s 12th Annual Meeting.
  • Excipients: Excipients in medicines for children: scientific and regulatory paradigms
    Ali Al-khattawi, Postdoctoral Research Associate, Aston University and Afzal R. Mohammed, Senior Lecturer in Pharmaceutics, Aston University

The digital version of Issue #2 2014 is restricted - login or subscribe free to access

European Pharmaceutical Review Issue 3 2022Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here